Peer-influenced content. Sources you trust. No registration required. This is HCN.
MDLinx
Fluvoxamine reduced fatigue and improved quality-of-life measures in adults with long COVID in a randomized placebo-controlled trial. The findings provide evidence for a potential therapy, although further research is needed to define optimal patient selection and treatment strategies.
Infectious Diseases July 31st 2026
DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS